Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7306 to 7320 of 7707 results

  1. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

  2. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

  3. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

  4. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

  5. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

  6. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

  7. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development [GID-TA10745] Expected publication date: 17 July 2024

  8. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    In development [GID-TA11411] Expected publication date: TBC

  9. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

  10. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

  11. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development [GID-TA11482] Expected publication date: TBC

  12. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

  13. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

  14. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

  15. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC